GLSI (Greenwich LifeSciences) OCF Margin %: 0.00% (As of Mar. 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $21.53
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences OCF Margin %?

Greenwich LifeSciences GLSI -6.78% 33 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Greenwich LifeSciences ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Greenwich LifeSciences's Cash Flow from Operations for the three months ended in Mar. 2026 was $-4.70 Mil. Greenwich LifeSciences's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Greenwich LifeSciences's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Greenwich LifeSciences's current OCF Yield % is -4.06%.

The historical rank and industry rank for Greenwich LifeSciences's OCF Margin % or its related term are showing as below:


GLSI's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Greenwich LifeSciences OCF Margin % Related Terms

Greenwich LifeSciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences OCF Margin % Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Greenwich LifeSciences's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.913/0
= %

Greenwich LifeSciences's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.702/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Greenwich LifeSciences (GLSI) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Greenwich LifeSciences and its competitors. According to the industry distribution chart, Greenwich LifeSciences ranks #999999 out of 959 companies in the Biotechnology industry.
Is Greenwich LifeSciences' OCF Margin % too high?
Greenwich LifeSciences' current OCF Margin % is 0.00%. Based on the distribution chart, Greenwich LifeSciences ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' OCF Margin % compare to LRMR and RGNX?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #999999 out of 959 companies for OCF Margin %. This places Greenwich LifeSciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price